Earnings ·
Xilio Therapeutics reports $10M Q3 revenue, $5.9M net loss; doses first patient in XTX501 trial
XLOXilio Therapeutics, Inc.
Xilio Therapeutics reported financial results for the quarter ended September 30, 2026, showing collaboration and license revenue of $10.0 million, a decrease from $19.1 million in the prior-year period. The company posted a net loss of $5.9 million, narrowing significantly from a $16.3 million loss in Q3 2025, driven by a $4.8 million gain on the change in fair value of warrant liabilities and lower operating expenses relative to revenue declines. Cash and cash equivalents stood at $122.2 million as of September 30, with management estimating sufficient runway into the first quarter of 2028. Pipeline updates included dosing the first patient in a Phase 1/2 trial for XTX501, a PD-1/masked IL-2 bispecific, and plans to submit IND applications for masked TCE programs XTX602 and XTX701 in late 2027. The company operates as a clinical-stage biotechnology firm developing masked immuno-oncology therapies.